The most prominent example is Ciltacabtagene Autoleucel (Carvykti), a VHH-based CAR-T therapy targeting BCMA, which received FDA approval in 2022 for the treatment of relapsed or refractory multiple myeloma [18]. The gene discussed is TNFRSF17; the disease is AL amyloidosis.